NEW YORK ( TheStreet) -- SciClone Pharmaceuticals (Nasdaq: SCLN) hit a new 52-week high Thursday as it is currently trading at $6.45, above its previous 52-week high of $6.40 with 66,025 shares traded as of 10:02 a.m. ET. Average volume has been 497,900 shares over the past 30 days.

SciClone has a market cap of $344 million and is part of the health care sector and drugs industry. Shares are up 45.5% year to date as of the close of trading on Wednesday.

SciClone Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in the People's Republic of China and internationally. The company has a P/E ratio of 14.5, above the average drugs industry P/E ratio of 14.1 and below the S&P 500 P/E ratio of 17.7.
  • Practice your SCLN trading strategies and win cash in our stock game.

TheStreet Ratings rates SciClone as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full SciClone Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.